Insider Trading Arrangements |
3 Months Ended |
|---|---|
|
Mar. 31, 2026
shares
| |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | On March 13, 2026, Harlan Robins, Chief Scientific Officer, adopted a Rule 10b5-1 trading plan. Dr. Robins’s plan provides for the sale of up to 984,800 shares of our common stock until December 31, 2026. This plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and our policies regarding transactions in our securities. On March 16, 2026, Kyle Piskel, Chief Financial Officer, terminated a Rule 10b5-1 trading plan that had been adopted on August 28, 2025 and provided for the sale of up to 173,901 shares of common stock and 100% of the net vested shares of our common stock received in connection with the vesting of certain restricted stock units. The plan was originally scheduled to expire on June 30, 2026. No further transactions will occur under the terminated plan. |
| Harlan Robins [Member] | |
| Trading Arrangements, by Individual | |
| Name | Harlan Robins |
| Title | Chief Scientific Officer |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | March 13, 2026 |
| Expiration Date | December 31, 2026 |
| Aggregate Available | 984,800 |
| Kyle Piskel [Member] | |
| Trading Arrangements, by Individual | |
| Name | Kyle Piskel |
| Title | Chief Financial Officer |
| Rule 10b5-1 Arrangement Terminated | true |
| Termination Date | March 16, 2026 |
| Expiration Date | June 30, 2026 |
| Aggregate Available | 173,901 |